<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392106</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-003</org_study_id>
    <nct_id>NCT00392106</nct_id>
  </id_info>
  <brief_title>High Intensity Focused Ultrasound (HIFU) Ablation System Study</brief_title>
  <official_title>Study of Focused Circumferential UltraSound for the Treatment of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProRhythm, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProRhythm, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is
      effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best
      medical therapy with FDA approved antiarrhythmic drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia affecting an
      estimated 2.2 million persons in the United States (US). In addition to being debilitating,
      AF has been identified as a leading risk factor for stroke. AF is often associated with
      structural heart disease, but a substantial number of AF patients have little or no
      detectable structural heart disease. A patient with AF is up to 5 times more likely to have a
      stroke than the general population.

      Recently, it has been demonstrated that for a significant portion of AF patients (80% - 95 %)
      the arrhythmia originates in one of the four pulmonary veins (PV's). Furthermore, it has been
      shown that isolation of this arrhythmia by ablation can, in the majority of patients
      (50-70%), eliminate or markedly reduce episodes of AF. Currently, there are a number of
      modalities being investigated to treat AF. They include radiofrequency, laser, thermal, cryo,
      microwave, and ultrasound ablation of targeted areas in the atrium and/or PVs.

      Comparison(s): Clinical success of High Intensity Focused Ultrasound (HIFU) Ablation for
      Pulmonary Vein Isolation in the treatment of Atrial Fibrillation, compared to medical therapy
      with anti-arrhythmic drugs (AADs).
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    voluntarily by Sponsor to investigate an anticipated SAE
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute treatment with elimination of AF episodes</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death, stroke, and hospitalization for recurrence of AF</measure>
    <time_frame>within 12 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute treatment success</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Class I or III anti-arrhythmic drug for the treatment of AF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmonary vein ablation with HIFU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propafenone</intervention_name>
    <description>Anti-arrhythmic drug prescribed for treatment of atrial fibrillation</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Rhyhmol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flecainide</intervention_name>
    <description>Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Tambocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dofetilide</intervention_name>
    <description>Anti-arrhythmic drug prescribed for treatment of atrial fibrillation</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Tikosyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sotolol</intervention_name>
    <description>Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Betapace</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulmonary vein ablation</intervention_name>
    <description>Electrical isolation of pulmonary vein with high-intensity focused ultrasound</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Left atrial ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Pacerone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented atrial fibrillation

          -  Failed or intolerant to at least 1 anti-arrhythmic drug

          -  Able to take anti-coagulant therapy

          -  Able to complete screening tests required for inclusion/exclusion criteria

          -  Able to take at least 1 approved anti-arrhythmic drug

          -  Not pregnant

          -  Available for follow-up for at least 12 months

        Exclusion Criteria:

          -  Persistent or permanent atrial fibrillation

          -  Mitral disease

          -  Prior surgical treatment for atrial fibrillation

          -  Ablation for treatment of atrial fibrillation within 6 months

          -  Severe left ventricular hypertrophy

          -  Known untreated coagulopathy

          -  Unstable angina

          -  Prior stroke

          -  Uncontrolled heart failure

          -  Secondary causes of atrial fibrillation

          -  Uncorrected hyperthyroidism within 12 months

          -  Pulmonary embolism within 6 months

          -  Pneumonia or acute pulmonary disease within 3 months

          -  Pacemaker/ICD

          -  High risk for esophageal disease

          -  Currently enrolled in investigational drug or device study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren Jackman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma University Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugh Calkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fullerton Vascular Medical Group</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexington Central Baptist Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hopsital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Systems</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Heart Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homolka Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2006</study_first_submitted>
  <study_first_submitted_qc>October 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2006</study_first_posted>
  <last_update_submitted>June 16, 2008</last_update_submitted>
  <last_update_submitted_qc>June 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Reinhard Warnking, President and CEO</name_title>
    <organization>ProRhythm, Inc.</organization>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>arrhythmia</keyword>
  <keyword>AF ablation</keyword>
  <keyword>antiarrhythmic agent</keyword>
  <keyword>catheter ablation</keyword>
  <keyword>pulmonary veins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dofetilide</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Flecainide</mesh_term>
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
    <mesh_term>Propafenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

